Thymosin Alpha-1 Research: What 962 Studies Show (2026) | RetatrutideCompare

Thymosin Alpha-1 — 962 studies indexed on PubMed. Activates Toll-like receptor 9 on plasmacytoid dendritic cells, restoring T-helper 1 immunity in immunocompromised states. Half-life: ~2 hours. FDA status: Not FDA-approved (orphan drug status; approved in EU, Asia).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Thymosin Alpha-1?

There are approximately 962 studies indexed on PubMed that mention Thymosin Alpha-1 (Tα1, Zadaxin), based on a search last updated 2026-06-18.

Is Thymosin Alpha-1 FDA-approved?

FDA status: Not FDA-approved (orphan drug status; approved in EU, Asia).

How does Thymosin Alpha-1 work?

Activates Toll-like receptor 9 on plasmacytoid dendritic cells, restoring T-helper 1 immunity in immunocompromised states.

Activates Toll-like receptor 9 on plasmacytoid dendritic cells, restoring T-helper 1 immunity in immunocompromised states.

Reference facts

Also known as
Tα1, Zadaxin, Thymalfasin
Category
Immune Modulator
Mechanism of action
Activates Toll-like receptor 9 on plasmacytoid dendritic cells, restoring T-helper 1 immunity in immunocompromised states.
Targets
TLR9, T-cell maturation
Indications under research or approved
Hepatitis B (approved 35+ countries), Hepatitis C, sepsis, immune support in cancer (off-label/research)
Regulatory status (reference entry)
Not FDA-approved (orphan drug status; approved in EU, Asia)
Half-life
~2 hours
Sequence
SDAAVDTSSEITTKDLKEKKEVVEEAEN
Sequence notes
28-residue acetylated peptide derived from prothymosin alpha; N-terminal acetylated.
Molecular weight (Da)
3108
Originator / sponsor
SciClone Pharmaceuticals
First reported
1972

Primary References

Explore research articles about Thymosin Alpha-1

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.